Katlyn McGrattan talks about a post-hoc analysis demonstrating that treatment with onasemnogene abeparvovec can achieve good bulbar function in patients with symptomatic SMA type 1 (3:55).
Katlyn McGrattan talks about a post-hoc analysis demonstrating that treatment with onasemnogene abeparvovec can achieve good bulbar function in patients with symptomatic SMA type 1 (3:55).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.medwireNews Deputy Bureau Chief
© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.